SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-20-003600
Filing Date
2020-02-13
Accepted
2020-02-13 16:30:18
Documents
1
Group Members
VIVO CAPITAL IX, LLCVIVO OPPORTUNITY, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G sc13g0220a1vivoven6_kalvista.htm SC 13G/A 83778
  Complete submission text file 0001213900-20-003600.txt   85669
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SC 13G/A | Act: 34 | File No.: 005-88797 | Film No.: 20611101
SIC: 2834 Pharmaceutical Preparations

Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 (650) 688-0818
Vivo Ventures VI, LLC (Filed by) CIK: 0001469547 (see all company filings)

IRS No.: 208829402 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SC 13G/A